Development of biosimilars in an era of oncologic drug shortagesEdward Li, Scott Anderson, Dolca Thomas et al.|Drug Design Development and Therapy|2015Cited by 41
Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune ThrombocytopeniaDavid J. Kuter, Nichola Cooper, Ralph V. Boccia et al.|Blood|2019Cited by 16